

Bibliography:

- Lincoff AM MD, Brown-Frandsen MD et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*, 2023; 389:2221-2232: Doi 10.1056/nejmoa2307563
- Centers for Disease Control and Prevention. Overweight & Obesity. Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion. Updated February 17, 2022. Accessed 2/19/2024. <https://www.cdc.gov/obesity/index.html>
- Acosta A, Streett S, Kroh MD et al. White Paper AGA: POWER – practice guide on obesity and weight management, education, and resources. *Clin Gastroenterol Hepatol*. 2017;15(5):631.e10.doi:10.1016/j.cgh.2016.10.023
- Hales CM, Carroll MD, Fryar CD et al. National Center for Health Statistics (NCHS) Data Brief 360. February 2020. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. Accessed May 5/25/2022. <https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf>
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2015; 100(2):342-362. doi: 10.1210/jc.2014-3415
- Acosta A. Streett S, Kroh MD et al. White Paper AGA: POWER – practice guide on obesity and weight management, education, and resources. *Clin Gastroenterol Hepatol*. 2017;15(5):631-649e10. Doi. 10.1016/j.cgh.2016.10.023
- American Diabetes Association (ADA). Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes. *Diabetes Care*. 2021;44(Suppl.1) S100-S110.
- Haddock CK, Poston WSC, Dill PL et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. *Int J Obes*. 2002;26(2):262-273. doi: 10.1038/sj.ijo.0801889
- Product Information: Saxenda (liraglutide) injection, for subcutaneous use. Novo Nordisk A/S., Bagsvaerd, Denmark. Revised 06/2022. Accessed February 19, 2024.
- Product Information: Wegovy (semaglutide) injection, for subcutaneous use. Novo Nordisk A/S., Bagsvaerd, Denmark. Revised 06/2021. Accessed February 19, 2024.
- Product Information: Ozempic (semaglutide) injection, for subcutaneous use. Novo Nordisk A/S., Bagsvaerd, Denmark. Revised 03/2022. Accessed February 19, 2024.
- Product Information: Rybelsus (semaglutide) tablets, for oral use. Novo Nordisk A/S., Bagsvaerd, Denmark. Revised 09/2019. Accessed February 19, 2024.
- Product Information: Mounjaro (tirzepatide) injection, for subcutaneous use. Lilly USA, LLC, Indianapolis, IN 46285. 5/2022. Accessed February 19, 2024
- IPD Analytics. Wegovy. New Drug Approval Review. June 2021. July 11, 2022. <https://www.ipdanalytics.com>
- Product Information: Zepbound (tirzepatide) injection, for subcutaneous use. Lilly USA, LLC, Indianapolis, IN 46285. 11/2023. Accessed February 19, 2024.
- IPD Analytics. Zepbound. New Drug Review. December 5, 2023. February 19, 2024. <https://www.ipdanalytics.com>
- American Diabetes Association. (2022, January). Standards of Medical Care in Diabetes. (M. Matthew C. Riddle, Ed.) *The Journal of Clinical and Applied Research and Education Diabetes Care*, 45(1), 1-264. Retrieved from www.diabetes.org/diabetescare.

- Giselle Hamad, M. (2021, May 4). *Bariatric surgery: Postoperative and long-term management of the uncomplicated patient*. (D. Jones, MD, & W. Chen, MD, PhD, Eds.) Retrieved from UpToDate: https://www.uptodate.com/contents/bariatric-surgery-postoperative-and-long-term-management-of-the-uncomplicated-patient/print?search=bariatric%20surgery&topicRef=587&source=see_link.
- IBM Corporation 2022. (2019, December 6). *IBM Micromedex*. Retrieved from IBM Micromedex: https://www.micromedexolutions.com/micromedex2/librarian/CS/2B094B/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/DF466F/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert. Inter med.
- Mechanick, MD, FACP, FACN, MACE, J. I., Apovian, MD, C., Brethauer, MD, S., Garvey, MD, FACE, W., Joffe, DO, FCCM, A. M., Kim, MD, J., . . . Still, DO, FACN, FACP, C. D. (2019, October 31). Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology,. *Surgery for Obesity and Related Diseases*, 16(2), 175-247. doi:<https://doi.org/10.1016/j.soard.2019.10.025>.
- Mechanick, MD, J. I., Youdim, MD, A., Jones, MD, MS, D. B., Garvey, MD, W., Hurley, MD, D. L., McMahon, MD, M., . . . Brethauer, MD, S. (2013). Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient - 2013 Update: Cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society. *National Institute of Health*, 19(2), 337-372. doi:10.4158/EP12437.GL.
- Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. M., Zimmet, P. Z., . . . Cummings, D. E. (2016, June). Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. *Diabetes Care*, 39, 861-877. doi:10.2337/dc16-0236
- Smith, K. M., & Miller, A. D. (2006). Medication and nutrient administration considerations after bariatric surgery. *American Society of Health-System Pharmacists*, 1852-1857.
- Leong, R. *et al.* (2022) 'Direct oral anticoagulants after bariatric surgery—what is the evidence?', *Journal of Thrombosis and Haemostasis*, 20(9), pp. 1988–2000. doi:10.1111/jth.15823.
- Kushnir, M. *et al.* (2023) 'Direct oral XA inhibitors for the treatment of venous thromboembolism after bariatric surgery', *Blood Advances*, 7(2), pp. 224–226. doi:10.1182/bloodadvances.2021006696.
- Gunka B, Mackenzie D, Doumouras A, Mithoowani S. Pharmacokinetics of direct oral anticoagulants after bariatric surgery: A retrospective cohort study [abstract]. <https://abstracts.isth.org/abstract/pharmacokinetics-of-direct-oral-anticoagulants-after-bariatric-surgery-a-retrospective-cohort-study/>. Accessed May 21, 2024.
- Patel PH, Ho T, Upadhyay SM. A Systematic Review of Warfarin Use in Post-Bariatric Surgery Patients: Cases Compiled From a Literature Review. *Annals of Pharmacotherapy*. 2023;57(2):193-197. doi:10.1177/10600280221105312.
- Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders: Indications for Metabolic and Bariatric Surgery. *Surg Obes Relat Dis*. 2022;18(12):1345-56. <https://doi.org/10.1016/j.soard.2022.08.013>

- Skogar ML, Sundbom M. Nonsteroid anti-inflammatory drugs and the risk of peptic ulcers after gastric bypass and sleeve gastrectomy. *Surg Obes Relat Dis*. 2022 Jul;18(7):888-93. doi: 10.1016/j.soard.2022.03.019.
- Begian A, Samaan JS, Hawley L, et al. The use of nonsteroidal anti-inflammatory drugs after sleeve gastrectomy. *Surg Obes Relat Dis*. 2021;17(3):484-88. <https://doi.org/10.1016/j.soard.2020.11.016>.